Treating Patients with Antipsychotics: an Individualized Management
Introduction: Subjective well-being, quality of life, cognition and psychosocial performance, including employment, have become endpoints of interest and goals for patients, families, clinicians and researchers. In this line, it is important to clarify the adverse effects caused by antipsychotics in order to innovate and complement treatment of patients with an individualize approach according to the patient’s needs and predispositions.
Objectives: Discuss new treatment’s way for patients using antipsychotics, elucidating the pros and cons of their use.
Results: Atypical antipsychotics cause weight gain and lead to a higher risk of diabetes and other metabolic sequelae than their typical counterparts. Besides, second-generation(atypical) has also shown adverse effects like: akathisia, sedation, abnormal metabolic laboratory results, and weight gain. On the other hand, talking about the fist-gentration (typical) antipsychotics, their clinical effectiveness is challenged by increased acute and chronic extrapyramidal side effects and related symptoms of dysphoria, compared to second-generation (atypical) antipsychotics. In addition, available evidence indicates that antipsychotic medications increase the risk of cerebrovascular adverse events (CVAEs) and death when used to treat elderly patients with Behavioral and Psychological Symptoms of Dementia (BPSD). Besides, some studies show that patient populations that are prescribed antipsychotic agents have a higher cardiovascular mortality rate than the general population. Considering that, we can see that each psychotic patient will need an individualized treatment according to their physical, social and psychological limitations and needs, leading us to realize the signifiance of this paper since it emphasizes the holistic management of this kind of patient.
Conclusion: With the aim of known safety concerns and uncertainty over long-term risks and benefis, it is clear the need to reevaluate clinical practice standard and strengthen efforts to educate especially primary care physicians, concerning the known safety and effiacy of antipsychotic medications to give the patients a treatment that is based on their quality of life.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).